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Abstract
Background: Patients with diabetes mellitus (DM) and chronic kidney disease (CKD) constitute
to be a high-risk population for the development of contrast-induced nephropathy (CIN), in which
the incidence of CIN is estimated to be as high as 50%. We performed this trial to assess the
efficacy of N-acetylcysteine (NAC) in the prevention of this complication.
Methods: In a prospective, double-blind, placebo controlled, randomized clinical trial, we studied
90 patients undergoing elective diagnostic coronary angiography with DM and CKD (serum
creatinine ≥ 1.5 mg/dL for men and ≥ 1.4 mg/dL for women). The patients were randomly assigned
to receive either oral NAC (600 mg BID, starting 24 h before the procedure) or placebo, in adjunct
to hydration. Serum creatinine was measured prior to and 48 h after coronary angiography. The
primary end-point was the occurrence of CIN, defined as an increase in serum creatinine ≥ 0.5 mg/
dL (44.2 μmol/L) or ≥ 25% above baseline at 48 h after exposure to contrast medium.
Results: Complete data on the outcomes were available on 87 patients, 45 of whom had received
NAC. There were no significant differences between the NAC and placebo groups in baseline
characteristics, amount of hydration, or type and volume of contrast used, except in gender (male/
female, 20/25 and 34/11, respectively; P = 0.005) and the use of statins (62.2% and 37.8%,
respectively; P = 0.034). CIN occurred in 5 out of 45 (11.1%) patients in the NAC group and 6 out
of 42 (14.3%) patients in the placebo group (P = 0.656).
Conclusion: There was no detectable benefit for the prophylactic administration of oral NAC
over an aggressive hydration protocol in patients with DM and CKD.
Trial registration: NCT00808795
Published: 29 June 2009
Trials 2009, 10:45 doi:10.1186/1745-6215-10-45
Received: 12 October 2008
Accepted: 29 June 2009
This article is available from: http://www.trialsjournal.com/content/10/1/45
© 2009 Amini et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Trials 2009, 10:45 http://www.trialsjournal.com/content/10/1/45
Page 2 of 6
(page number not for citation purposes)
Background
Contrast-induced nephropathy (CIN) is the third most
common cause of hospital acquired acute kidney injury,
accounting for 10% of all cases[1]. With the increasing use
of contrast media in diagnostic and interventional proce-
dures, it has become one of the major challenges encoun-
tered during routine cardiovascular practice. Generally,
this form of acute kidney injury follows a benign course
and only rarely necessitates use of dialysis [2-4]. Neverthe-
less, use of radiocontrast media has been associated with
increased in-hospital morbidity, mortality, and costs of
medical care, long admission, especially in patients need-
ing dialysis [5-8]. Patients at the greatest risk for CIN can
be defined as those that have preexisting impaired renal
function and diabetes mellitus with the incidence esti-
mated to be as high as 50% [9]. Therefore, these patients
constitute to be an appropriate target population for
efforts at prevention of this important complication. Pre-
ventive therapies primarily include limitation of contrast
exposure, intravenous volume expansion with a saline
solution, and use of low- or iso-osmolality contrast media
[10]. However, since these measures provide incomplete
protection for CIN, interest has emerged in a number of
adjunction short-term pharmacotherapy methods.
Among them, N-acetylcysteine (NAC) has been of consid-
erable interest after an initial report by Tepel et al. [11].
They showed a reduction in the incidence of CIN with
NAC compared with hydration alone. Up to now, several
clinical studies [9,12-26] and meta-analyses [27-37] have
been performed to assess the efficacy of NAC in the pre-
vention of CIN, but the results are widely controversial
even among the meta-analyses. In spite of heterogeneity
in the available data on the efficacy of NAC, several stud-
ies have advised the use of NAC, especially in high-risk
patients, because of its low cost, availability, and few side
effects. It, however, seems that we need more evidence
about the efficacy and cost-effectiveness of NAC in
patients at high risk for the development of CIN to make
rational clinical decisions for individual patients as well as
policy decisions for the health of the general public.
The purpose of this study was to extend our understand-
ing of the potentials of NAC in the prevention of CIN in
patients with diabetes mellitus and chronic kidney dis-
ease.
Methods
Study patients
Between April 2006 and October 2006, ninety consecu-
tive eligible patients scheduled for elective diagnostic cor-
onary angiography at the cardiac catheterization
laboratory of "Tehran Heart Center" (Tehran University of
Medical Sciences) were enrolled in this study. We
included patients older than 18 years old with a history of
diabetes mellitus for at least one year and chronic kidney
disease, defined as serum creatinine concentration ≥ 1.5
mg/dL for men and ≥ 1.4 mg/dL for women. Patients with
acute coronary syndrome requiring primary or rescue cor-
onary intervention within less than 12 h, cardiogenic
shock, current peritoneal or hemodialysis, or a known
allergy to NAC were excluded from the study. The study
protocol was approved by the ethics committees of
Tehran University of Medical Sciences and Tehran Heart
Center, and written informed consent was obtained from
all the patients.
Study protocol
The study was a prospective, double-blind, placebo con-
trolled, randomized clinical trial. The patients were ran-
domly assigned on a 1:1 fashion via the balanced block
randomization method using computer generated ran-
dom numbers to receive NAC or placebo by randomly
drawing sealed envelopes containing either the active
drug or matching placebo. NAC and placebo were pre-
pared by Darmanyab Co. (agency of Zambon Group
S.p.A, Milan, Italy) matched in appearance, packing, and
way of use. NAC was orally administered at the dose of
600 mg twice a day, starting 24 h before the procedure
(two doses before and two doses after the procedure). The
patients were hydrated orally and intravenously. All the
patients were encouraged to drink fluids like water and
fruit juice for at least 8 glasses over 12 h before the proce-
dure and memorize the number of glasses. The oral pre-
procedural hydration was estimated by multiplying the
number of glasses drunk by 200 mL (estimated volume of
a glass). In addition, the patients were hydrated intrave-
nously by 1 L of 0.9 normal saline, which was com-
menced in the catheterization laboratory. Serum
creatinine and urea nitrogen concentrations were meas-
ured prior to coronary angiography and 48 h after the pro-
cedure. Serum creatinine concentration prior to coronary
angiography was referred to as the baseline level. Creati-
nine clearance (CrCl) was estimated with the Cockcroft-
Gault formula, where CrCl = ([140-age]*weight(kg)/
serum creatinine(mg/dL)*72), with adjustment for
female sex (CrClfemale = CrCl*0.85)[38]. Coronary angiog-
raphies were performed with the low osmolar nonionic
contrast medium Iohexol (Omnipaque; Amersham
Health, Co. Cork, Ireland) or the iso-osmolar nonionic
contrast medium Iodixanol (Visipaque;GE Healthcare,
Co. Cork, Ireland) and/or the high osmolar ionic medium
Diatrizoate meglumine/sodium (Urografin; Schering AG,
Berlin, Germany).
End-points
The primary end-point of the study was the occurrence of
CIN, defined as an increase in serum creatinine concentra-
tion ≥ 0.5 mg/dL(44.2 μmol/L) or ≥ 25% above the base-
line at 48 h after exposure to the contrast medium[5,11].
The secondary end-points were: (1) the change in serumTrials 2009, 10:45 http://www.trialsjournal.com/content/10/1/45
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creatinine 48 h after exposure to the contrast agent; (2) the
change in serum urea nitrogen 48 h after the procedure;
and (3) the change in CrCl 48 h after coronary angiogra-
phy.
Statistical analysis
According on the study of Tepel et al[11], a sample size of
42 patients in each group would be sufficient to detect a
difference of 19% between the groups in the rate of CIN
at 48 h after exposure to the contrast medium, with 80%
power and a 5% significance level. This 19% difference
represents the difference between a 21% CIN rate in the
placebo group and a 2% rate in the treatment group. This
number has been increased to 45 per group to allow for a
predicted drop-out from treatment of around 5%.
Data distribution was checked by histogram and the Kol-
mogorov-Smirnov test.
The continuous data were expressed as mean ± SD and
were compared via the Student t-test. The categorical data
were expressed as number and percentage and were com-
pared via the Chi-square test or Fischer exact test. Two
tailed P < 0.05 was considered significant. The data were
analyzed with SPSS software, version 13.0 (SPSS Inc, Chi-
cago, Illinois, USA).
Results
Patients
Of the 90 patients enrolled in the study, 3 patients in pla-
cebo group were lost to follow-up because of immediate
hospital discharge after coronary angiography and failure
to have subsequent blood sampling performed. Thus,
only 42 patients were evaluable for the assessment of the
outcomes in the placebo group. We present the baseline
clinical, pharmacological, and laboratory characteristics
of the study patients in Table 1.
There were no significant differences between the treat-
ment groups with regard to CHD risk factors, baseline
serum creatinine, and urea nitrogen concentration or CrCl
except for the gender, which was significantly different
between the two groups of patients (P = 0.005). Also, with
respect to concomitant medications, there were no signif-
icant differences between the NAC group and placebo
group except in the use of statins (62.2% versus 37.8%
respectively, P = 0.034). Cardiac catheterization data, con-
sisting of type and dose of the contrast agents, are shown
in Table 2. Since 22 patients received a combination of
Diatrizoate meglumine/sodium with Iohexol or Iodixa-
nol, we also calculated the total dose of contrast in each
group. There were no significant differences between the
two groups in regard to the type and dose of the radiocon-
trast agents administered for coronary angiography (P for
all > 0.05).
Primary end-point
CIN, defined as an increase in serum creatinine concentra-
tion of ≥ 0.5 mg/dL or ≥ 25% above the baseline, was not
significantly different between the NAC and placebo
groups (5/45 [11.1%] vs. 6/42 [14.3%], respectively; rela-
tive risk: 0.78 [95% CI: 0.26–2.36]; P = 0.656).
Table 1: Baseline clinical, pharmacological, and laboratory characteristics of study patientsa
NAC group(n = 45) Placebo group(n = 45) P value
Baseline clinical characteristics
Age, years 63.25 ± 9.78 65.09 ± 9.40 0.45
Sex (male/female) 20/25 34/11 0.005
Body mass index, kg/m2 28.56 ± 4.81 27.85 ± 4.13 0.45
Time since diagnosis of DM, years 10.11 ± 8.50 9.82 ± 7.57 0.86
Systolic blood pressure, mmHg 156.05 ± 19.9 151.95 ± 18.4 0.34
Diastolic blood pressure, mmHg 82.63 ± 7.60 81.22 ± 7.14 0.39
Ejection fraction, % 49.45 ± 10.99 46.83 ± 14.15 0.37
Medications
Aspirin, n(%) 37(82.2%) 36(80%) 1.00
ACE-inhibitors/ARB, n(%) 32(71.1%) 30(66.7%) 0.82
β-blockers, n(%) 29(64.4%) 35(77.8%) 0.24
Nitrates, n(%) 30(66.7%) 30(66.7%) 1.00
Diuretics, n(%) 23(51.1%) 19(42.2%) 0.52
Statins, n(%) 28(62.2%) 17(37.8%) 0.034
Digitals, n(%) 6(13.3%) 6(13.3%) 1.00
Baseline laboratory values
Serum creatinine, mg/dL 1.736 ± 0.42 1.736 ± 0.17 1.00
Serum urea nitrogen, mg/dL 60.56 ± 28.37 58.64 ± 28.94 0.75
Creatinine clearance, mL/min 42.76 ± 11.97 43.97 ± 11.91 0.63
a All plus-minus values are mean ± SD. DM, diabetes mellitus; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blockers.Trials 2009, 10:45 http://www.trialsjournal.com/content/10/1/45
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Secondary end-point
No difference was observed between the groups regarding
the secondary end-points. The changes in serum creati-
nine, serum urea nitrogen, and CrCl 48 h after coronary
angiography were similar between the groups. The data
are presented in Table 3.
Discussion
The potential of NAC to reduce the risk of CIN has been a
topic of intense and recent interest, manifested by the
number of prospective clinical trials on this topic [9,12-
26]. This is likely, in part, due to the absence of effective
adjunctive pharmacotherapy methods for this important
complication. However, it seems likely that the potential
for benefit from NAC, low cost, and the absence of consid-
erable data indicating potential harm also have contrib-
uted to make NAC advisable, not least in high-risk
patients, before a definitive demonstration of meaningful
clinical benefit on the incidence of CIN and its morbidity
and mortality.
In this study, we evaluated the efficacy of NAC exclusively
in high-risk patients for the development of CIN. The
main finding of the current study was that the prophylac-
tic oral administration of NAC did not provide any benefit
as compared with a placebo to reduce the incidence of
CIN in patients with chronic kidney disease and diabetes
mellitus, who are a high-risk population for the develop-
ment of CIN. Our findings are consistent with those in
studies reporting that NAC provides no benefit over
hydration for the prevention of CIN
[12,13,15,17,20,22,23]. In addition, our study supports
and expands the studies by Coyle et al[26], Durham et al.
[17], and Gomes et al. [9,24], who evaluated the efficacy
of NAC in the prevention of CIN in diabetic patients. They
concluded that NAC provided no benefit over an aggres-
sive hydration protocol in this population and also sug-
gested that this intervention could even be harmful. But,
on the other hand, there are several clinical studies report-
ing findings that do not chime with ours
[9,16,18,19,21,22,25]. Previously, a post-hoc analysis of a
subgroup of 75 diabetic patients [21] indicated that NAC
might effectively prevent CIN in patients with diabetes
mellitus but our study did not confirm this finding.
What are we to make of such conflicting results? Fishbane
et al. [39]compared positive and negative studies and
noted that the studies showing no benefit for NAC had a
Table 2: Cardiac catheterization dataa
NAC group (n = 45) Placebo group (n = 45) P value
Preprocedural hydration, mL 2254 ± 633 2272 ± 602 0.89
Type of radiocontrast agent
Iohexol, n(%) 32(72%) 34(76%) 1.00
Iodixanol, n(%) 1(2%) 0(0%) 1.00
Diatrizoate meglumine/sodium, n(%) 0(0%) 1(2%) 0.88
Diatrizoate meglumine/sodium+Iodixanol, n(%) 1(2%) 1(2%) 1.00
Diatrizoate meglumine/sodium+Iohexol, n(%) 11(24%) 9(20%) 0.82
Dose of radiocontrast agent
Iohexol, mL 100.11 ± 37.80 102.22 ± 40.43 0.37
Iodixanol, mL 6.11 ± 28.78 1.56 ± 10.43 0.32
Diatrizoate meglumine/sodium, mL 11.78 ± 20.48 17.33 ± 36.51 0.79
Total, mL 118.00 ± 35.20 121.11 ± 43.95 0.71
a All plus-minus values are mean ± SD.
Table 3: Primary and secondary end-points after coronary angiographya
NAC group(n = 45) Placebo group(n = 45b) P value
Primary end-point
Incidence of CIN, n(%) 5(11.1%) 6(14.3%) 0.656
Secondary end-points
Change in serum creatinine, mg/dL -0.016 ± 0.363 -0.018 ± 0.467 0.975
Change in serum urea nitrogen, mg/dL -1.73 ± 24.03 -3.71 ± 24.26 0.703
Change in creatinine clearance, mL/min 2.86 ± 8.84 3.78 ± 10.87 0.676
a All plus-minus values are mean ± SD. CIN, contrast-induced nephropathy.
bWhile 45 patients were enrolled in each group, serum creatinine and urea nitrogen measurements were not available for 3 placebo patients who 
were discharged immediately after coronary angiography and did not return for subsequent blood sampling (comparison, 45 NAC patients vs. 42 
placebo patients).Trials 2009, 10:45 http://www.trialsjournal.com/content/10/1/45
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much lower incidence of CIN in the placebo group than
did those studies showing NAC to be beneficial (11.0%
compared to 24.8%). These results suggest that perhaps
NAC is only beneficial for those at a high risk of CIN. Be
that as it may, in this study we were unable to show a ben-
efit resulting from the prophylactic administration of oral
NAC in a high-risk group of patients with diabetes melli-
tus and chronic renal insufficiency (mean baseline creati-
nine 1.74 mg/dL).
The incidence of CIN is currently estimated to be as high
as 40–50% amongst patients with diabetes mellitus and
preexisting renal disease [6,9,16]. In this study, the overall
incidence of CIN was 12.6%, which is significantly lower
than that in previous reports. The low incidence of CIN in
our study may have several reasons: (1) our patients were
hydrated orally by a mean volume of 2267 ± 645 mL of
fluids over the 12-h period before the procedure followed
by 1 L of IV 0.9 normal saline beginning in the catheteri-
zation laboratory. In comparison, the other studies
reporting a higher incidence of CIN, have typically used
lower amounts of hydration [9,40,41], which may be
insufficient for maximal protection from contrast nephro-
toxicity. (2) The mean dose of contrast agents used in our
study was lower than that of other studies. Over 95% of
the patients in our study received Iohexol at least in part
and the mean total dose of Iohexol used in our study was
about 100 mL, while it has typically been used by
amounts of 140 mL to 280 mL in the previous studies
[15,25,42].
Limitations
Several limitations should be noted. The current study
protocol excluded patients with acute coronary syndrome,
requiring primary or rescue coronary intervention within
the first 12 h and cardiogenic shock, and therefore the
effect of NAC was not explored in these patient subsets.
The relatively small sample size of this study calls for cau-
tion interpreting the results. This sample size was prede-
termined from a power calculation based on the findings
of Tepel et al[11]. They found a 19% difference in the rate
of CIN between NAC and placebo groups, which was
more extreme than what others have cited in favor of
NAC. Another potential limitation of this study is that,
although there were no significant differences between
the NAC group and placebo group with regard to the type
of the contrast agents used, the multiplicity of the type of
the contrast agents was a potential limitation of this study.
Conclusion
Our major finding was that NAC had no advantage over
an aggressive hydration protocol in patients with diabetes
mellitus and chronic renal insufficiency undergoing diag-
nostic coronary angiography. On the basis of these find-
ings, we believe that the use of NAC to prevent CIN in this
population should not be encouraged. Our findings sup-
port that the recommended measures for preventing CIN
continue to be appropriate hydration, even greater than
the standard regimen for hydration, and the use of a small
volume of contrast in patients with a high risk of CIN
undergoing coronary angiography.
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